The verdict
Our read at a glance.
Whether a withdrawn oral steroid with documented cholestatic liver injury has any defensible non-medical use.
- The signal
- Its real clinical history is narrow and genuine: stanozolol was used for hereditary angioedema, where androgens raise C1 inhibitor levels, and it appeared in dermatology and paediatric growth contexts, including combination work in central precocious puberty. It has no modern approved product in the United States. The rest of its literature is a warning label written by researchers: stanozolol-induced bland cholestasis, hepatotoxicity in animals, neurotoxic effects in rat hippocampus, and a large body of anti-doping metabolite work driven by how long its metabolites persist in urine.
- The unknown
- Whether there is any exposure at which the hepatic and lipid effects are acceptable in a healthy person, which is unanswerable because nobody is running that trial.
- Our read
- A drug that had a real medical job, lost it, and survives entirely in the grey market. When a compound's own PubMed record includes the phrase induced bland cholestasis, the burden of proof is not on the person declining to take it.
The mechanism
How it works.
Stanozolol is a dihydrotestosterone derivative carrying two modifications: a pyrazole ring fused to the A ring, and a 17-alpha methyl group. The pyrazole ring blocks aromatisation entirely, so there is no oestradiol produced from it, and the 17-alpha methyl group lets it survive the first pass through the liver so it can be taken orally. That second modification is where the harm comes from. 17-alpha-alkylated androgens interfere with bile transport in hepatocytes, which is the mechanism behind the cholestatic pattern of injury described in its case literature, and they induce hepatic lipase, which is why HDL cholesterol falls so sharply. The same structure that makes the drug work by mouth is the structure that damages the organ it passes through.
Safety & regulatory boundary
The consequential part.
No current FDA-approved human product in the United States; a Schedule III controlled substance. Documented cholestatic liver injury in published case reports. Severe suppression of HDL cholesterol, characteristic of 17-alpha-alkylated orals. Tendon and joint complaints are widely reported by users and poorly characterised in the literature. Prohibited in sport at all times, and historically one of the most-detected agents in doping control.
What's next
What we're watching.
Nothing in development. The relevant surveillance is continued case reporting of liver injury from black-market product.
Context
Why this is discussed.
It is the classic cutting oral, it is cheap, and it carries the cultural weight of being the drug that got Ben Johnson stripped in 1988.
The evidence base
10 cited references.
Indexed literature (PubMed)10
Helfman T et al. · J Am Acad Dermatol · 1995
Ampuero J et al. · Gastroenterol Hepatol · 2014
Göschl L et al. · Drug Test Anal · 2021
Zhu S et al. · Front Endocrinol (Lausanne) · 2021
LIS M et al. · Sem Med · 1963
Brickman CM et al. · Int J Dermatol · 1983
Karimooy FN et al. · Biomol Concepts · 2019
Mowaad NA et al. · Cardiovasc Toxicol · 2024
Ozcagli E et al. · Int J Mol Med · 2018
de Andrade TU et al. · Basic Clin Pharmacol Toxicol · 2019
Keep reading